Randomized, open-label, multicenter, active-controlled study to evaluate the safety and efficacy of virologically suppressed subjects who switch from a FTC/TDF regimen to tenofovir alafenamide (TAF)-containing regimen in achieving HIV-1 RNA < 50 copies/mL at Week 48 as defined by the FDA snapshot analysis in HIV-1 infected subjects.